Platelet-derived TGF-β as well as direct platelet-tumor cell contacts synergistically activate the TGF-β/Smad and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways in cancer cells, resulting in their transition to an invasive mesenchymal-like phenotype and enhanced metastasis in vivo (124) (Figure 3). Here, TGFB1 is linked to cancer.